Osteoarthritis
Top in rheumatology: Platelet-rich plasma injections, OA drug pipeline
A speaker at the 2021 OARSI World Congress said intraarticular injections of platelet-rich plasma or cell therapies could be effective alternatives to traditional modalities for osteoarthritis. It was the top story in rheumatology last week.
Study offers alternative explanation to placebo effect in assessing pain in OA
The placebo effect on pain scores in osteoarthritis may be attributed to a phenomenon called “regression to the mean,” according to a speaker at the 2021 OARSI World Congress.
Tanezumab comparable to NSAIDs in WOMAC pain, function across OA patient subgroups
Two dosing regimens of tanezumab yielded comparable outcomes in pain and function as NSAIDs across a number of osteoarthritis patient subgroups, according to a speaker at the 2021 OARSI World Congress virtual meeting.
Great Debate: Joint tissue impacts nerves, or vice versa, in OA
This year’s iteration of the Great Debate at the OARSI 2021 World Congress centered on the role of nerves in pain, functionality and pathogenesis of osteoarthritis.
COVID-19 raises profile, utility of digital therapeutic approaches in OA
The COVID-19 pandemic forced the rheumatology community to adopt a number of telehealth and digital approaches in patient care, according to a speaker at the 2021 OARSI World Congress virtual meeting.
Mesenchymal stem cell injections represent cutting edge of OA intervention
Intra-articular injections of mesenchymal stem cells into the synovium may yield expression of a number of genes that inhibit progression of osteoarthritis, according to a speaker at the 2021 OARSI World Congress virtual meeting.
Obesity, OA share 'bidirectional' relationship as drivers of pain, inflammation
Pain in obese individuals with osteoarthritis is caused by biomechanical and inflammatory processes and may involve depression, according to a speaker at the 2021 OARSI World Congress.
'Personalized' use of platelet-rich plasma injections may be the future of OA treatment
Understanding the complex associations between pain, function and structural factors in the joints may allow clinicians to use intraarticular injections more effectively in osteoarthritis, according to a speaker at the 2021 OARSI World Congress.
OARSI president spotlights efforts toward ‘year-round’ OA community engagement
The Osteoarthritis Research Society International continues to thrive despite setbacks presented by the pandemic, according to the organization’s president, Ali Mobasheri, DPhil (Oxon), who opened the 2021 OARSI World Congress.
Osteoarthritis drug pipeline rattles as FDA rejects top contender: What comes next?
Progress toward effective drug therapies is often marked with failure; yet even among a host of difficult-to-treat arthritis conditions, osteoarthritis has received a disproportionate share of therapeutic setbacks and disappointing clinical trials.